(Reuters) - Merck & Co reported better-than-expected quarterly results, with sales of newer drugs mostly offsetting declining sales of drugs facing generic competition.
via elEconomista Mercados http://ift.tt/1pAisZQ http://ift.tt/eA8V8J
via elEconomista Mercados http://ift.tt/1pAisZQ http://ift.tt/eA8V8J
No hay comentarios:
Publicar un comentario